This work is licensed under a Creative Commons Attribution 4.0 International License.
AP
General Information
DRACP ID DRACP00233
Peptide Name AP
Sequence ACDCRGDCFCGGGGIVRRADRAAVP
Sequence Length 25
UniProt ID Not available
PubChem CID Not available
Origin Endostatin derived Synthetic
Type Synthetic peptide
Classification
Active ACP Cancer targeted peptides
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| B16-F10 | Mouse melanoma | Carcinoma | 50% inhibition at 2.5µg/ml | MTT assay | 72 h | 1 |
| B16-F10 | Mouse melanoma | Carcinoma | 40% inhibition at 5µg/ml | MTT assay | 72 h | 1 |
| B16-F10 | Mouse melanoma | Carcinoma | 75% inhibition at 10µg/ml | MTT assay | 72 h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target integrin αvβ3
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C100H165N37O32S4
Absent amino acids EHKLMNQSTWY
Common amino acids G
Mass 295418
Pl 7.92
Basic residues 4
Acidic residues 3
Hydrophobic residues 8
Net charge 1
Boman Index -5280
Hydrophobicity 3.2
Aliphatic Index 54.8
Half Life
Mammalian: 30 hour
Yeast: >20 hour
E.coli: >10 hour
Extinction Coefficient cystines 250
Absorbance 280nm 10.42
Polar residues 9
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 20515045
Title Effect of RGD-4C Position is More Important Than Disulfide Bonds on Antiangiogenic Activity of RGD-4C Modified Endostatin Derived Synthetic Polypeptide
Year 2010
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.